BEYOND MEAT, INC. (NASDAQ: BYND) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Beyond Meat, Inc. Investors of Upcoming Deadline
globenewswire.com
Want to monitor BYSI?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor BYSIBeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring's lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.